NYSE
Novo Nordisk A/S (NVO)
♥ 602 Thanks from members
Novo Nordisk A/S faces divided sentiment with the stock down over 50% from its peak, pressured by Q2 earnings declines and intense competition from Eli Lilly, yet drawing value buyers following rapid Wegovy pill adoption and revised 2026 guidance.